Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T14:51:24.064Z.
Calculation as of: 2026-10-06T14:51:24.064Z.
Quote observation: 2026-10-06T14:50:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 412370d08cb3fb7a3c2e4d636897a8ea9259835d42853a062d33098765049a4f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$376.61M
EV/FCF Ratio
N/A
TTM Avg
17.00x
3Y Avg
16.36x
5Y Avg
16.36x
Market Cap
$384.11M
EV/FCF Ratio
N/A
TTM Avg
1559.86x
3Y Avg
1559.86x
5Y Avg
273.86x
Market Cap
$357.49M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$354.67M
EV/FCF Ratio
N/A
TTM Avg
6.23x
3Y Avg
6.23x
5Y Avg
6.23x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Canopy Growth Corporation (CGC) | $371.03M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $376.61M | N/A | 17.00x | 16.36x | 16.36x |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $379.97M | N/A | N/A | N/A | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $385.63M | N/A | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $356.64M | N/A | N/A | N/A | N/A |
| Orthofix Medical Inc. (OFIX)vs › | $384.11M | N/A | 1559.86x | 1559.86x | 273.86x |
| Embecta Corp. (EMBC)vs › | $353.89M | 9.97x | 9.65x | 69.46x | 48.92x |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $357.49M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $354.67M | N/A | 6.23x | 6.23x | 6.23x |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $350.32M | N/A | 50.02x | 37.43x | 35.40x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
